NATERA INC
NASDAQ: NTRA (Natera, Inc.)
Last update: 2 days ago, 3:42PM154.48
5.92 (3.98%)
| Previous Close | 148.56 |
| Open | 148.35 |
| Volume | 769,622 |
| Avg. Volume (3M) | 1,718,627 |
| Market Cap | 20,883,531,776 |
| Price / Sales | 10.34 |
| Price / Book | 15.91 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Profit Margin | -11.22% |
| Operating Margin (TTM) | -13.60% |
| Diluted EPS (TTM) | -1.53 |
| Quarterly Revenue Growth (YOY) | 53.00% |
| Total Debt/Equity (MRQ) | 15.65% |
| Current Ratio (MRQ) | 4.00 |
| Operating Cash Flow (TTM) | 135.66 M |
| Levered Free Cash Flow (TTM) | 92.85 M |
| Return on Assets (TTM) | -8.96% |
| Return on Equity (TTM) | -19.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Natera, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -3.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.40 |
|
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 3.45% |
| % Held by Institutions | 93.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management Llc | 31 Dec 2024 | 4,431,609 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 251.00 (RBC Capital, 62.48%) | Buy |
| Median | 192.50 (24.61%) | |
| Low | 185.00 (Morgan Stanley, 19.76%) | Buy |
| Average | 202.33 (30.98%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 123.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 09 May 2025 | 190.00 (22.99%) | Buy | 0.000 |
| 10 Apr 2025 | 160.00 (3.57%) | Buy | 143.28 | |
| RBC Capital | 13 Mar 2025 | 251.00 (62.48%) | Buy | 142.51 |
| Morgan Stanley | 05 Mar 2025 | 185.00 (19.76%) | Buy | 147.92 |
| Piper Sandler | 04 Mar 2025 | 205.00 (32.70%) | Buy | 142.35 |
| Baird | 28 Feb 2025 | 188.00 (21.70%) | Buy | 155.59 |
| Canaccord Genuity | 28 Feb 2025 | 195.00 (26.23%) | Buy | 155.59 |
| 26 Feb 2025 | 180.00 (16.52%) | Buy | 160.56 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BROPHY MICHAEL BURKES | - | 154.48 | -5,063 | -782,132 |
| CHAPMAN STEVEN LEONARD | - | 154.48 | -13,183 | -2,036,510 |
| FESKO JOHN | - | 154.48 | -1,709 | -264,006 |
| MARCUS GAIL BOXER | - | 154.48 | -4,000 | -617,920 |
| MOSHKEVICH SOLOMON | - | 154.48 | -5,281 | -815,809 |
| RABINOWITZ DANIEL | - | 154.48 | -1,993 | -307,879 |
| RABINOWITZ MATTHEW | - | 154.48 | -1,718 | -265,397 |
| SHEENA JONATHAN | - | 154.48 | -439 | -67,817 |
| Aggregate Net Quantity | -33,386 | |||
| Aggregate Net Value ($) | -5,157,469 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 154.48 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOSHKEVICH SOLOMON | Officer | 01 May 2025 | Automatic sell (-) | 3,000 | 154.48 | 463,440 |
| CHAPMAN STEVEN LEONARD | Officer | 01 May 2025 | Automatic sell (-) | 6,980 | 154.48 | 1,078,270 |
| MARCUS GAIL BOXER | Director | 01 May 2025 | Automatic sell (-) | 4,000 | 154.48 | 617,920 |
| MARCUS GAIL BOXER | Director | 01 May 2025 | Option execute | 4,000 | - | - |
| BROPHY MICHAEL BURKES | Officer | 29 Apr 2025 | Automatic sell (-) | 3,045 | 154.48 | 470,392 |
| CHAPMAN STEVEN LEONARD | Officer | 28 Apr 2025 | Automatic sell (-) | 6,203 | 154.48 | 958,239 |
| BROPHY MICHAEL BURKES | Officer | 28 Apr 2025 | Automatic sell (-) | 2,018 | 154.48 | 311,741 |
| SHEENA JONATHAN | Director | 28 Apr 2025 | Automatic sell (-) | 439 | 154.48 | 67,817 |
| FESKO JOHN | Officer | 28 Apr 2025 | Automatic sell (-) | 1,709 | 154.48 | 264,006 |
| MOSHKEVICH SOLOMON | Officer | 28 Apr 2025 | Automatic sell (-) | 2,206 | 154.48 | 340,783 |
| MOSHKEVICH SOLOMON | Officer | 28 Apr 2025 | Disposed (-) | 75 | 154.48 | 11,586 |
| RABINOWITZ DANIEL | Officer | 28 Apr 2025 | Automatic sell (-) | 1,993 | 154.48 | 307,879 |
| RABINOWITZ MATTHEW | Officer | 28 Apr 2025 | Automatic sell (-) | 1,718 | 154.48 | 265,397 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |